A phase II trial of dovitinib in previously-treated advanced pleural mesothelioma: The Ontario Clinical Oncology Group
Authors:
- Scott A. LaurieSLScott A. Laurie
- Desiree HaoDesiree Hao
- Natasha B. LeighlNLNatasha B. Leighl
- John GoffinJohn Goffin
- Abderrahim KhomaniAKAbderrahim Khomani
- Ashish GuptaAGAshish Gupta
- Christina L. AddisonCAChristina L. Addison
- Anita BaneABAnita Bane
- Jean SeelyJean Seely
- Marc L. FilionMFMarc L. Filion
- Gregory R. PondGPGregory R. Pond
- Mark N. LevineMLMark N. Levine
- 1 February 2017
- journal article
- Published by Elsevier in Lung Cancer
- Vol. 104, 65-69
Abstract
No abstract availableKeywords
Funding Information
- Novartis for the conduct of this study
This publication has 27 references indexed in Scilit:
- Bevacizumab for newly diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 3 trialThe Lancet, 2016
- A Phase II Study of Intermittent Sunitinib Malate as Second-Line Therapy in Progressive Malignant Pleural MesotheliomaJournal of Thoracic Oncology, 2012
- Brief Report: A Phase II Study of Sunitinib in Malignant Pleural Mesothelioma. The NCIC Clinical Trials GroupJournal of Thoracic Oncology, 2011
- A Phase II Study of Sorafenib in Malignant Mesothelioma: Results of Cancer and Leukemia Group B 30307Journal of Thoracic Oncology, 2010
- New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)European Journal of Cancer, 2009
- Randomized Phase III Study of Cisplatin With or Without Raltitrexed in Patients With Malignant Pleural Mesothelioma: An Intergroup Study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of CanadaJournal of Clinical Oncology, 2005
- In vivo Target Modulation and Biological Activity of CHIR-258, a Multitargeted Growth Factor Receptor Kinase Inhibitor, in Colon Cancer ModelsClinical Cancer Research, 2005
- Modified RECIST criteria for assessment of response in malignant pleural mesotheliomaAnnals of Oncology, 2004
- Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural MesotheliomaJournal of Clinical Oncology, 2003
- EVALUATION OF TUMOUR ANGIOGENESIS AS A PROGNOSTIC MARKER IN MALIGNANT MESOTHELIOMAThe Journal of Pathology, 1997